Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00249873




Registration number
NCT00249873
Ethics application status
Date submitted
4/11/2005
Date registered
7/11/2005
Date last updated
15/06/2015

Titles & IDs
Public title
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
Scientific title
A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation
Secondary ID [1] 0 0
EFC4912 A
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atrial Fibrillation 0 0
Vascular Risk 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - clopidogrel (SR25990C)
Treatment: Drugs - placebo

Experimental: Clopidogrel + ASA - Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)

Placebo Comparator: Placebo + ASA - Matching placebo of clopidogrel 75 mg od plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)


Treatment: Drugs: clopidogrel (SR25990C)
oral administration (tablets)

Treatment: Drugs: placebo
oral administration (tablets)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death as Per Adjudication
Timepoint [1] 0 0
expected median follow-up of approximately 3 years
Secondary outcome [1] 0 0
Occurrence of Stroke
Timepoint [1] 0 0
expected median follow-up of approximately 3 years
Secondary outcome [2] 0 0
Death From Any Cause (Cardiovascular and Noncardiovascular)
Timepoint [2] 0 0
expected median follow-up of approximately 3 years
Secondary outcome [3] 0 0
Adjudicated Major Bleedings
Timepoint [3] 0 0
expected median follow-up of approximately 3 years

Eligibility
Key inclusion criteria
To be eligible for ACTIVE A patients must have in same time the three following conditions
:

- Evidence of atrial fibrillation either on one current Electrocardiogram (ECG) or two
ECGs recorded at two weeks a part during 6 months prior to study enrollment.

- Evidence of high risk of vascular events : at least one of the following risk criteria
must be present :

- are 75 years greater;

- on treatment for systemic hypertension;

- prior stroke, Transient Ischemic Attack (TIA) or non-Central Nervous System
(non-CNS) systemic embolus;

- left ventricular dysfunction with left ventricular ejection fraction (EF)
estimated by echocardiogram or angiogram (radionuclide or contrast) to be < 45%;

- peripheral vascular disease (previous peripheral artery revascularization, limb
and foot amputation, or the combination of current intermittent claudication and
ankle arm systolic blood pressure ratio < 0.9);

- age 55 to 74 years and either; f1) diabetes mellitus requiring drug therapy, or
f2) documented previous myocardial infarction or documented coronary artery
disease.

- To have either a contraindication to use an oral anticoagulant treatment or they are
unwilling to take an oral anticoagulant treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Patients will be excluded from ACTIVE if any of the following are present :

- requirement for clopidogrel (such as recent coronary stent procedure)

- requirement for oral anticoagulant (such as prosthetic mechanical heart valve);

- prior intolerance to ASA or clopidogrel;

- documented peptic ulcer disease within the previous 6 months;

- prior intracerebral hemorrhage;

- significant thrombocytopenia; (platelet count < 50 x 10(9)/L)

- psychosocial reason making study participation impractical;

- geographic reason making study participation impractical;

- ongoing alcohol abuse;

- mitral stenosis,

- pregnant or nursing woman or woman of child bearing potential and not on effective
birth control for at least one month prior to start of study or not willing to
continue on birth control for duration of study; (severe comorbid condition such that
the patient is not expected to survive 6 months;

- patient currently receiving an investigational pharmacologic agent;

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2003
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2009
Sample size
Target
Accrual to date
Final
7554
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Sanofi-Aventis Administrative Office - Macquarie Park
Recruitment postcode(s) [1] 0 0
- Macquarie Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New Jersey
Country [2] 0 0
Argentina
State/province [2] 0 0
Buenos Aires
Country [3] 0 0
Austria
State/province [3] 0 0
Wien
Country [4] 0 0
Belgium
State/province [4] 0 0
Diegem
Country [5] 0 0
Brazil
State/province [5] 0 0
Sao Paulo
Country [6] 0 0
Canada
State/province [6] 0 0
Laval
Country [7] 0 0
Chile
State/province [7] 0 0
Santiago
Country [8] 0 0
Czech Republic
State/province [8] 0 0
Praha
Country [9] 0 0
Denmark
State/province [9] 0 0
Horsholm
Country [10] 0 0
Finland
State/province [10] 0 0
Helsinki
Country [11] 0 0
France
State/province [11] 0 0
Paris
Country [12] 0 0
Germany
State/province [12] 0 0
Berlin
Country [13] 0 0
Greece
State/province [13] 0 0
Athens
Country [14] 0 0
Hong Kong
State/province [14] 0 0
Causeway Bay
Country [15] 0 0
Hungary
State/province [15] 0 0
Budapest
Country [16] 0 0
Italy
State/province [16] 0 0
Milano
Country [17] 0 0
Malaysia
State/province [17] 0 0
Kuala Lumpur
Country [18] 0 0
Mexico
State/province [18] 0 0
Mexico
Country [19] 0 0
Netherlands
State/province [19] 0 0
Gouda
Country [20] 0 0
Norway
State/province [20] 0 0
Lysaker
Country [21] 0 0
Poland
State/province [21] 0 0
Warszawa
Country [22] 0 0
Portugal
State/province [22] 0 0
Porto Salvo
Country [23] 0 0
Singapore
State/province [23] 0 0
Singapore
Country [24] 0 0
South Africa
State/province [24] 0 0
Midrand
Country [25] 0 0
Spain
State/province [25] 0 0
Barcelona
Country [26] 0 0
Sweden
State/province [26] 0 0
Bromma
Country [27] 0 0
Switzerland
State/province [27] 0 0
Geneva
Country [28] 0 0
Taiwan
State/province [28] 0 0
Taipei
Country [29] 0 0
United Kingdom
State/province [29] 0 0
Guildford Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sanofi
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Bristol-Myers Squibb
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily
(od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily
recommended dose) for preventing vascular events such as stroke and heart attack during
approximately three years of follow-up in patients with atrial fibrillation associated with
at least one major risk factor of vascular event such as elderly, blood pressure increase,
history of stroke or transient ischemic attack or left ventricular dysfunction etc. The study
will also accept patients with atrial fibrillation and unwilling to take oral anticoagulant
therapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00249873
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Philippe YUSUF, Prof.
Address 0 0
Hamilton Health Sciences Corporation
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00249873